IMW 2021 | BiTE and CAR-T combinations for myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses the prospects of combining chimeric antigen receptor (CAR) T-cell therapy with bispecific T-cell engagers (BiTEs) and other novel agents such as immunomodulatory imide drugs (IMiDs) for the treatment of myeloma. Prof. Raje explains that the use of BiTEs in conjunction with CAR-T may deepen response and minimalize treatment duration, particularly if paired with IMiDs, which have demonstrated extremely high potency. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Noopur Raje, MD, has participated in consulting for Amgen, BMS, GSK, Janssen, Takeda, Oncopeptides, Karyopharm, Bluebird Bio, Pfizer, AstraZeneca; has participated in the advisory boards of Immuneel and Caribou; and has received research funding from Bluebird Bio,
